MannKind Corporation (MNKD) revealed on Friday that the Food and Drug Administration (FDA) approved its inhaled insulin, AFREZZA, used for improving glycemic control caused by diabetes mellitus in adult patients. MannKind Corporation (NASDAQ:MNKD) weekly performance is -2.64%. On last trading day company shares ended up $10.32. Analysts mean target price for the company is $9.06. MannKind Corporation (NASDAQ:MNKD) distance from 50-day simple moving average is 23.40%.
Investment analysts at Jefferies Group hoisted their price target on shares of Arrowhead Research Corp (NASDAQ:ARWR) from $29.00 to $30.00 in a note issued to investors on Friday. The firm currently has a “buy” rating on the stock. Jefferies Group’s price target would suggest a potential upside of 95.19% from the stock’s previous close. Arrowhead Research Corp (NASDAQ:ARWR) shares fell -5.10% in last trading session and ended the day on $13.58. ARWR its return on assets is -47.50%. Arrowhead Research Corp (NASDAQ:ARWR) quarterly performance is -25.71%.
Synageva BioPharma Corp (NASDAQ:GEVA) a Lexington company developing therapeutic products for rare diseases, reported positive results in a Phase 3 trial of sebelipase alfa in 66 children and adults with a disorder called LAL Deficiency. Synageva BioPharma Corp (NASDAQ:GEVA) shares moved down -13.69% in last trading session and was closed at $90.45, while trading in range of $88.70-$98.61. Synageva BioPharma Corp (NASDAQ:GEVA) year to date performance is 39.76%.
Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) announced preclinical data Monday morning demonstrating the promise of DCR-PH1, for the treatment of primary hyperoxaluria type 1, a rare inherited liver disorder. Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) ended the last trading day at $21.03. Company weekly volatility is calculated as 8.33% and price to cash ratio as 2.79. Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) showed a positive weekly performance of 17.22%.
Leave a Reply